[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

ME03079B - Ligandi modifikovani cirkularnom permutacijom као agonisтi i antagonisti - Google Patents

Ligandi modifikovani cirkularnom permutacijom као agonisтi i antagonisti

Info

Publication number
ME03079B
ME03079B MEP-2018-155A MEP2018155A ME03079B ME 03079 B ME03079 B ME 03079B ME P2018155 A MEP2018155 A ME P2018155A ME 03079 B ME03079 B ME 03079B
Authority
ME
Montenegro
Prior art keywords
agonists
antagonists
circular permutation
ligands modified
ligands
Prior art date
Application number
MEP-2018-155A
Other languages
German (de)
English (en)
French (fr)
Inventor
Juan Alvarez
Jean Chamoun
Original Assignee
Alkermes Pharma Ireland Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alkermes Pharma Ireland Ltd filed Critical Alkermes Pharma Ireland Ltd
Publication of ME03079B publication Critical patent/ME03079B/me

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4727—Mucins, e.g. human intestinal mucin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5412—IL-6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5443—IL-15
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/545—IL-1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/57563—Vasoactive intestinal peptide [VIP]; Related peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/90—Fusion polypeptide containing a motif for post-translational modification
    • C07K2319/91—Fusion polypeptide containing a motif for post-translational modification containing a motif for glycosylation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cell Biology (AREA)
  • Pulmonology (AREA)
  • Reproductive Health (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Neurology (AREA)
MEP-2018-155A 2012-06-08 2013-06-06 Ligandi modifikovani cirkularnom permutacijom као agonisтi i antagonisti ME03079B (me)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US201261657378P 2012-06-08 2012-06-08
US201261657285P 2012-06-08 2012-06-08
US201261657264P 2012-06-08 2012-06-08
US201261723081P 2012-11-06 2012-11-06
US201361778575P 2013-03-13 2013-03-13
US201361778812P 2013-03-13 2013-03-13
PCT/US2013/044556 WO2013184942A1 (en) 2012-06-08 2013-06-06 Ligands modified by circular permutation as agonists and antagonists
EP13801437.8A EP2859015B1 (en) 2012-06-08 2013-06-06 Ligands modified by circular permutation as agonists and antagonists

Publications (1)

Publication Number Publication Date
ME03079B true ME03079B (me) 2019-01-20

Family

ID=49712642

Family Applications (1)

Application Number Title Priority Date Filing Date
MEP-2018-155A ME03079B (me) 2012-06-08 2013-06-06 Ligandi modifikovani cirkularnom permutacijom као agonisтi i antagonisti

Country Status (21)

Country Link
US (8) US9296801B2 (me)
EP (5) EP3401402B1 (me)
JP (7) JP6234446B2 (me)
AU (3) AU2013271545C1 (me)
CA (3) CA2869787C (me)
CY (2) CY1120522T1 (me)
DK (2) DK2859015T3 (me)
ES (4) ES2842677T3 (me)
HK (3) HK1203820A1 (me)
HR (2) HRP20180914T1 (me)
HU (2) HUE037849T2 (me)
LT (2) LT2859015T (me)
ME (1) ME03079B (me)
NZ (4) NZ630848A (me)
PL (2) PL2859015T3 (me)
PT (2) PT2859015T (me)
RS (2) RS61391B1 (me)
SI (2) SI3401402T1 (me)
SM (2) SMT202100007T1 (me)
TR (2) TR201809046T4 (me)
WO (3) WO2013184939A2 (me)

Families Citing this family (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ630848A (en) * 2012-06-08 2016-07-29 Alkermes Inc Fusion polypeptides comprising an active protein linked to a mucin-domain polypeptide
MA40721A (fr) * 2014-08-06 2017-06-13 The Univ Of Miami Protéines de fusion de l'interleukine-2/récepteur alpha de l'interleukine-2 et procédés d'utilisation
ES2824151T3 (es) 2014-12-19 2021-05-11 Alkermes Inc Proteínas de fusión Fc monocatenarias
US11938193B2 (en) 2016-01-08 2024-03-26 Washington University Compositions comprising chemerin and methods of use thereof
US10335459B2 (en) 2016-06-22 2019-07-02 Alkermes, Inc. Compositions for modulating IL-10 immunostimulatory and anti-inflammatory properties
EP3481412A4 (en) 2016-07-11 2020-03-18 The National Institute for Biotechnology in the Negev, Ltd. FUSION PROTEINS WITH EXTENDED SERUM HALF-VALUE
US11524985B2 (en) 2017-03-20 2022-12-13 Bio-Techne Corporation IL-37 fusion protein and methods of making and using same
KR101784288B1 (ko) * 2017-04-26 2017-10-11 (주)넥스젠바이오텍 피부 세포 증식 효과가 증가한 성장 분화 인자 11과 열 충격 단백질 10의 융합단백질 및 이를 유효성분으로 함유하는 피부 주름 개선용 화장료 조성물
KR101800200B1 (ko) 2017-05-26 2017-11-23 (주)넥스젠바이오텍 항산화 활성 및 피부 세포 증식 효과가 증가한 성장 분화 인자 11과 상피세포 성장인자의 융합단백질 및 이를 유효성분으로 함유하는 피부 주름 개선용 화장료 조성물
CA3064577A1 (en) 2017-06-27 2019-01-03 Codexis, Inc. Penicillin-g acylases
CN107362351B (zh) * 2017-09-04 2020-11-10 上海市儿童医院 Il-36r的拮抗剂在制备镇痛药物中的应用
IL275426B1 (en) 2017-12-19 2024-11-01 Xencor Inc Engineered il-2 fc fusion proteins
EP3741774A4 (en) 2018-01-19 2021-06-02 Pepgene Inc. N-TERMINAL FUSION APPROVED FOR THE PRODUCTION OF A RECOMBINANT POLYPEPTIDE, AND PROCESS FOR THE PRODUCTION OF A RECOMBINANT POLYPEPTIDE USING THE LATTER
CA3094112A1 (en) * 2018-03-28 2019-10-03 Bristol-Myers Squibb Company Interleukin-2/interleukin-2 receptor alpha fusion proteins and methods of use
EP3792276A4 (en) * 2018-04-26 2022-02-16 Good T Cells, Inc. NOVEL FUSION PROTEIN AND PHARMACEUTICAL COMPOSITION TO PREVENT OR TREAT CANCER THEREOF
CN108948178A (zh) * 2018-07-20 2018-12-07 安他杰（杭州）生物医药科技有限公司 一种改良的人il-37蛋白及其应用
CN109251896A (zh) * 2018-08-13 2019-01-22 中山大学 一株高表达hKLs-his蛋白的细胞株及其制备方法和应用
US11246906B2 (en) * 2019-06-11 2022-02-15 Alkermes Pharma Ireland Limited Compositions and methods for subcutaneous administration of cancer immunotherapy
CA3147757A1 (en) 2019-07-26 2021-02-04 Visterra, Inc. Interleukin-2 agents and uses thereof
JP7355326B2 (ja) * 2019-08-05 2023-10-03 デンカ株式会社 経粘膜投与薬剤
MX2022004577A (es) 2019-10-18 2022-05-10 Alkermes Pharma Ireland Ltd Agentes inmunomoduladores il-2 en combinacion con inhibidores de puntos de control inmune.
EP4065585A1 (en) 2019-11-25 2022-10-05 Alkermes, Inc. Substituted macrocyclic compounds and related methods of treatment
CA3164731A1 (en) 2019-12-20 2021-06-24 Regeneron Pharmaceuticals, Inc. Novel il2 agonists and methods of use thereof
CN116925237A (zh) * 2019-12-31 2023-10-24 北京质肽生物医药科技有限公司 Glp-1和gdf15的融合蛋白以及其缀合物
EP4093755A4 (en) * 2020-01-24 2024-07-31 Alkermes Pharma Ireland Limited PURIFICATION PROCESSES
WO2021194909A1 (en) * 2020-03-21 2021-09-30 Larix Biosciences, Llc Bispecific and trispecific functional molecules of ace2 and complement pathways and their use
MX2022012982A (es) * 2020-04-15 2023-03-06 Alkermes Pharma Ireland Ltd Agentes inmunoestimulantes en combinación con inhibidores de la angiogénesis.
IL297279A (en) * 2020-04-15 2022-12-01 Alkermes Pharma Ireland Ltd Immunostimulants in combination with blood vessel formation inhibitors
CN115997008A (zh) 2020-04-22 2023-04-21 艾欧凡斯生物治疗公司 协调用于患者特异性免疫疗法的细胞的制造的系统和方法
JP2023523855A (ja) 2020-05-04 2023-06-07 アイオバンス バイオセラピューティクス，インコーポレイテッド 腫瘍浸潤リンパ球の製造方法及び免疫療法におけるその使用
EP4146793A1 (en) 2020-05-04 2023-03-15 Iovance Biotherapeutics, Inc. Selection of improved tumor reactive t-cells
WO2021231316A1 (en) * 2020-05-11 2021-11-18 Alkermes Pharma Ireland Limited Il-2 fusion polypeptide compositions and methods of making and using the same
BR112022022869A2 (pt) * 2020-05-11 2023-01-31 Alkermes Pharma Ireland Ltd Composições de polipeptídeo de fusão de il-2 e métodos de fabricação e uso destas
CN111662973B (zh) * 2020-05-28 2023-08-25 广州医科大学附属第一医院（广州呼吸中心） 与慢性阻塞性肺疾病易感性辅助诊断相关的snp位点及其应用
CN111826400A (zh) * 2020-07-21 2020-10-27 中科宝承生物医学科技有限公司 一种双特异性抗体nk细胞制备方法及其细胞和应用
WO2022026358A1 (en) * 2020-07-27 2022-02-03 Arizona Board Of Regents On Behalf Of The University Of Arizona Multifunctional immunoglobulin-fold polypeptides from alternative translational initiation and termination
WO2022076606A1 (en) 2020-10-06 2022-04-14 Iovance Biotherapeutics, Inc. Treatment of nsclc patients with tumor infiltrating lymphocyte therapies
US20230372397A1 (en) 2020-10-06 2023-11-23 Iovance Biotherapeutics, Inc. Treatment of nsclc patients with tumor infiltrating lymphocyte therapies
WO2022098954A1 (en) 2020-11-06 2022-05-12 Nektar Therapeutics Tlr agonist compounds and related cancer immunotherapy methods
WO2022099695A1 (en) * 2020-11-16 2022-05-19 Jiangsu Cell Tech Medical Research Institute Co., Ltd. Cd164 fusion and uses thereof
US12098178B2 (en) 2020-12-04 2024-09-24 Visterra, Inc. Methods of using interleukin-2 agents
US20240131064A1 (en) 2020-12-11 2024-04-25 Iovance Biotherapeutics, Inc. Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with braf inhibitors and/or mek inhibitors
WO2022133140A1 (en) 2020-12-17 2022-06-23 Iovance Biotherapeutics, Inc. Treatment with tumor infiltrating lymphocyte therapies in combination with ctla-4 and pd-1 inhibitors
US20240123067A1 (en) 2020-12-17 2024-04-18 Iovance Biotherapeutics, Inc. Treatment of cancers with tumor infiltrating lymphocyte therapies
WO2022147196A2 (en) 2020-12-31 2022-07-07 Iovance Biotherapeutics, Inc. Devices and processes for automated production of tumor infiltrating lymphocytes
EP4284919A1 (en) 2021-01-29 2023-12-06 Iovance Biotherapeutics, Inc. Methods of making modified tumor infiltrating lymphocytes and their use in adoptive cell therapy
EP4288140A1 (en) 2021-02-05 2023-12-13 Iovance Biotherapeutics, Inc. Adjuvant therapy for cancer
JP2024509184A (ja) 2021-03-05 2024-02-29 アイオバンス バイオセラピューティクス，インコーポレイテッド 腫瘍保存及び細胞培養組成物
EP4308691A1 (en) 2021-03-19 2024-01-24 Iovance Biotherapeutics, Inc. Methods for tumor infiltrating lymphocyte (til) expansion related to cd39/cd69 selection and gene knockout in tils
CA3213163A1 (en) 2021-03-25 2022-09-29 Iovance Biotherapeutics, Inc. Methods and compositions for t-cell coculture potency assays and use with cell therapy products
EP4313312A1 (en) 2021-03-26 2024-02-07 Innate Pharma Multispecific proteins comprising an nkp46-binding site, a cancer antgienge binding site fused to a cytokine for nk cell engaging
IL307800A (en) 2021-04-19 2023-12-01 Iovance Biotherapeutics Inc Chimeric costimulatory receptors, chemokine receptors and their use in cellular immunotherapy
JP2024519029A (ja) 2021-05-17 2024-05-08 アイオバンス バイオセラピューティクス，インコーポレイテッド Ｐｄ－１遺伝子編集された腫瘍浸潤リンパ球及び免疫療法におけるその使用
MX2023014647A (es) 2021-06-09 2024-01-31 Innate Pharma Proteinas de union a nkp46 multiespecificas.
WO2022258678A1 (en) 2021-06-09 2022-12-15 Innate Pharma Multispecific proteins binding to nkp30, a cytokine receptor, a tumour antigen and cd16a
WO2022258691A1 (en) 2021-06-09 2022-12-15 Innate Pharma Multispecific proteins binding to nkg2d, a cytokine receptor, a tumour antigen and cd16a
JP2024526898A (ja) 2021-07-22 2024-07-19 アイオバンス バイオセラピューティクス，インコーポレイテッド 固形腫瘍断片の凍結保存のための方法
JP2024527961A (ja) 2021-07-28 2024-07-26 アイオバンス バイオセラピューティクス，インコーポレイテッド Ｋｒａｓ阻害剤と併用した腫瘍浸潤リンパ球療法によるがん患者の治療
CN113735980A (zh) * 2021-08-23 2021-12-03 中国医学科学院北京协和医院 一种自融合串联蛋白修饰方法及其应用
EP4398915A1 (en) 2021-09-09 2024-07-17 Iovance Biotherapeutics, Inc. Processes for generating til products using pd-1 talen knockdown
EP4404969A1 (en) 2021-09-24 2024-07-31 Iovance Biotherapeutics, Inc. Expansion processes and agents for tumor infiltrating lymphocytes
WO2023077015A2 (en) 2021-10-27 2023-05-04 Iovance Biotherapeutics, Inc. Systems and methods for coordinating manufacturing of cells for patient-specific immunotherapy
EP4430167A1 (en) 2021-11-10 2024-09-18 Iovance Biotherapeutics, Inc. Methods of expansion treatment utilizing cd8 tumor infiltrating lymphocytes
US20230151095A1 (en) 2021-11-12 2023-05-18 Xencor, Inc. Bispecific antibodies that bind to b7h3 and nkg2d
WO2023147486A1 (en) 2022-01-28 2023-08-03 Iovance Biotherapeutics, Inc. Tumor infiltrating lymphocytes engineered to express payloads
EP4469065A1 (en) 2022-01-28 2024-12-04 Iovance Biotherapeutics, Inc. Cytokine associated tumor infiltrating lymphocytes compositions and methods
WO2023196877A1 (en) 2022-04-06 2023-10-12 Iovance Biotherapeutics, Inc. Treatment of nsclc patients with tumor infiltrating lymphocyte therapies
WO2023201369A1 (en) 2022-04-15 2023-10-19 Iovance Biotherapeutics, Inc. Til expansion processes using specific cytokine combinations and/or akti treatment
WO2023220608A1 (en) 2022-05-10 2023-11-16 Iovance Biotherapeutics, Inc. Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with an il-15r agonist
WO2023235790A1 (en) * 2022-06-01 2023-12-07 University Of Miami Bifunctional il-2 and il-10 fusion proteins and uses thereof
WO2024011114A1 (en) 2022-07-06 2024-01-11 Iovance Biotherapeutics, Inc. Devices and processes for automated production of tumor infiltrating lymphocytes
CN117003852B (zh) * 2022-07-07 2024-11-05 北京大学 白细胞介素-2的拓扑改造及其作为自身免疫病药物的应用
WO2024030758A1 (en) 2022-08-01 2024-02-08 Iovance Biotherapeutics, Inc. Chimeric costimulatory receptors, chemokine receptors, and the use of same in cellular immunotherapies
TW202426634A (zh) 2022-09-09 2024-07-01 美商艾歐凡斯生物治療公司 使用ｐｄ─１／ｔｉｇｉｔ ｔａｌｅｎ雙重基因減弱生成ｔｉｌ產物之方法
TW202426633A (zh) 2022-09-09 2024-07-01 美商艾歐凡斯生物治療公司 使用ｐｄ－１／ｔｉｇｉｔ ｔａｌｅｎ雙重基因減弱生成ｔｉｌ產物之方法
CN117106024B (zh) * 2022-10-21 2024-05-24 南京市妇幼保健院 一种人血清多肽agdmp1及其在改善胰岛素抵抗中的应用
WO2024098027A1 (en) 2022-11-04 2024-05-10 Iovance Biotherapeutics, Inc. Methods for tumor infiltrating lymphocyte (til) expansion related to cd39/cd103 selection
WO2024102636A1 (en) 2022-11-07 2024-05-16 Xencor, Inc. Bispecific antibodies that bind to b7h3 and mica/b
WO2024112571A2 (en) 2022-11-21 2024-05-30 Iovance Biotherapeutics, Inc. Two-dimensional processes for the expansion of tumor infiltrating lymphocytes and therapies therefrom
WO2024118836A1 (en) 2022-11-30 2024-06-06 Iovance Biotherapeutics, Inc. Processes for production of tumor infiltrating lymphocytes with shortened rep step
EP4431525A1 (en) 2023-03-16 2024-09-18 Anaveon AG Il-2 fusion protein
WO2024133823A1 (en) 2022-12-22 2024-06-27 Anaveon AG Il-2 fusion protein
WO2025015318A2 (en) 2023-07-13 2025-01-16 Iovance Biotherapeutics, Inc. Cytokine encoding lentiviral vectors and uses thereof for making tumor infiltrating lymphocytes
WO2025019790A1 (en) 2023-07-19 2025-01-23 Iovance Biotherapeutics, Inc. Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with trop-2 targeting adc

Family Cites Families (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3992518A (en) 1974-10-24 1976-11-16 G. D. Searle & Co. Method for making a microsealed delivery device
US5916588A (en) 1984-04-12 1999-06-29 The Liposome Company, Inc. Peptide-containing liposomes, immunogenic liposomes and methods of preparation and use
IE60901B1 (en) 1986-08-21 1994-08-24 Vestar Inc Improved treatment of systemic fungal infections with phospholipid particles encapsulating polyene antifungal antibiotics
US5872095A (en) 1990-05-01 1999-02-16 Chiron Corporation IL-1 receptor antagonists medicaments
US5747444A (en) 1990-10-09 1998-05-05 Chiron Corporation Method of treating graft-versus-host disease
US5635599A (en) 1994-04-08 1997-06-03 The United States Of America As Represented By The Department Of Health And Human Services Fusion proteins comprising circularly permuted ligands
IT1270662B (it) 1994-10-13 1997-05-07 Applied Research Systems Antagonista della interleuchina-1
US5837495A (en) 1994-10-13 1998-11-17 Applied Research Systems Ars Holding N.V. DNA encoding interleukin-1 antagonist
US5660848A (en) 1994-11-02 1997-08-26 The Population Council, Center For Biomedical Research Subdermally implantable device
US5614191A (en) 1995-03-15 1997-03-25 The United States Of America As Represented By The Department Of Health And Human Services IL-13 receptor specific chimeric proteins and uses thereof
US6518061B1 (en) 1995-03-15 2003-02-11 The United States Of America As Represented By The Department Of Health And Human Services IL-13 receptor specific chimeric proteins and uses thereof
US6096728A (en) 1996-02-09 2000-08-01 Amgen Inc. Composition and method for treating inflammatory diseases
WO1998007409A1 (en) 1996-08-23 1998-02-26 Sequus Pharmaceuticals, Inc. Liposomes containing a cisplatin compound
JP2001503396A (ja) 1996-10-11 2001-03-13 アルザ コーポレイション 治療用リポソーム組成物および方法
US6056973A (en) 1996-10-11 2000-05-02 Sequus Pharmaceuticals, Inc. Therapeutic liposome composition and method of preparation
US5969105A (en) 1996-10-25 1999-10-19 Feng; Yiqing Stem cell factor receptor agonists
EP0939816A1 (en) 1996-10-25 1999-09-08 G.D. SEARLE & CO. Circularly permuted erythropoietin receptor agonists
US6294170B1 (en) 1997-08-08 2001-09-25 Amgen Inc. Composition and method for treating inflammatory diseases
JP2002526380A (ja) 1997-10-31 2002-08-20 バイオミラ，インコーポレイテッド 癌関連ｍｕｃ−１ムチン誘発免疫抑制の治療におけるｍｕｃ−１誘導体とその使用法
US6562347B1 (en) * 1998-03-12 2003-05-13 The United States Of America As Represented By The Department Of Health And Human Services Chemokine-tumor antigen fusion proteins as cancer vaccines
US6492492B1 (en) 1998-04-03 2002-12-10 University Of Washington Circularly permuted biotin binding proteins
EP1161274B1 (en) 1999-03-03 2004-12-29 Optinose AS Nasal delivery device
WO2001036489A2 (en) * 1999-11-12 2001-05-25 Merck Patent Gmbh Erythropoietin forms with improved properties
US6808902B1 (en) * 1999-11-12 2004-10-26 Amgen Inc. Process for correction of a disulfide misfold in IL-1Ra Fc fusion molecules
AU2001236475A1 (en) 2000-01-13 2001-07-24 Panorama Research, Inc. Circularly permutated, interaction-activated proteins
US6497870B1 (en) 2000-05-22 2002-12-24 Hyseq, Inc. Therapeutic uses of il-1 receptor antagonist
WO2001096565A2 (en) 2000-06-16 2001-12-20 Asterion Limited Binding agents: chimeric ligand/receptor proteins
CA2419954C (en) 2000-09-14 2012-01-03 Ares Trading S.A. Use of il-6r/il-6 chimera in huntington's disease
ES2311560T3 (es) * 2000-12-07 2009-02-16 Eli Lilly And Company Proteinas de fusion glp-1.
EP1357934A1 (en) 2001-02-06 2003-11-05 MERCK PATENT GmbH Modified interleukin-1 receptor antagonist (il-1ra) with reduced immunogenicity
JP4421894B2 (ja) 2001-07-20 2010-02-24 アブソーバー アクチボラゲット 血液型抗原融合ポリペプチドおよびその使用方法
US7214660B2 (en) * 2001-10-10 2007-05-08 Neose Technologies, Inc. Erythropoietin: remodeling and glycoconjugation of erythropoietin
US7157277B2 (en) * 2001-11-28 2007-01-02 Neose Technologies, Inc. Factor VIII remodeling and glycoconjugation of Factor VIII
IL147412A0 (en) * 2001-12-31 2002-08-14 Yeda Res & Dev The use of il6r/il6 chimera in nerve cell regeneration
JP4435575B2 (ja) * 2002-04-18 2010-03-17 イエダ リサーチ アンド ディベロップメント カンパニー リミテッド ＮＦ−κＢ誘導酵素の誘導体、その製法および使用
EP1517700B1 (en) * 2002-04-22 2012-03-28 Recopharma AB Mucin fusion polypeptide vaccines, compositions and methods of use thereof
US20080241166A1 (en) 2002-06-28 2008-10-02 Domantis Limited Ligands that bind a receptor
WO2004015057A2 (en) * 2002-08-09 2004-02-19 Recopharma Ab Mucin-immunoglobulin fusion proteins
US20040175359A1 (en) 2002-11-12 2004-09-09 Desjarlais John Rudolph Novel proteins with antiviral, antineoplastic, and/or immunomodulatory activity
EP1578782A4 (en) * 2002-12-30 2007-09-12 Amgen Inc COSTIMULATING FACTORIAL THERAPY
GB0315182D0 (en) * 2003-06-28 2003-08-06 Asterion Ltd Cytokine variant polypeptides
WO2005034863A2 (en) * 2003-10-03 2005-04-21 Jarikuma Corporation Countermeasures against malaria
US8129506B2 (en) * 2003-10-24 2012-03-06 Genzyme Corporation Modulation of the interaction of MUC1 with MUC1 ligands
US8454963B2 (en) * 2003-11-13 2013-06-04 Musc Foundation For Research Development Tissue targeted complement modulators
US7576183B2 (en) * 2003-12-24 2009-08-18 Los Alamos National Security, Llc Structure-based receptor MIMICS targeted against bacterial superantigen toxins
US8338138B2 (en) 2004-01-28 2012-12-25 The John Hopkins University Methods for making and using molecular switches involving circular permutation
HUE040595T2 (hu) 2004-04-02 2019-03-28 Swedish Orphan Biovitrum Ab Publ Eljárás IL-1ra aggregációjának csökkentésére
EP1781684A4 (en) 2004-08-25 2008-05-21 Amprotein Corp NEW CHIMERE POLYPEPTIDE AND USE THEREOF
EP1827462A4 (en) * 2004-11-24 2012-01-04 Therakine Ltd IMPLANT FOR INTRAOCULAR DRUG DELIVERY
WO2006086607A2 (en) 2005-02-10 2006-08-17 Emory University Novel proteins with enhanced functionality and methods of making novel proteins using circular permutation
EP1947111B1 (en) * 2005-08-12 2011-02-09 Riken Mucin glycoprotein and use thereof
EP1777294A1 (en) * 2005-10-20 2007-04-25 Institut National De La Sante Et De La Recherche Medicale (Inserm) IL-15Ralpha sushi domain as a selective and potent enhancer of IL-15 action through IL-15Rbeta/gamma, and hyperagonist (IL15Ralpha sushi -IL15) fusion proteins
JPWO2007063907A1 (ja) * 2005-11-30 2009-05-07 塩野義製薬株式会社 ペプチド糖鎖付加体およびそれを有効成分とする医薬
EP1792914B1 (en) * 2005-12-02 2009-07-29 Apceth GmbH & Co. KG Chemokine-mucin fusions linked to Glycosylphosphatidylinositol (GPI)-anchors in tissue regeneration and as tumour immune adjuvants
GB0606946D0 (en) 2006-04-06 2006-05-17 Asterion Ltd Polypeptide antagonist
US20100063258A1 (en) 2006-06-28 2010-03-11 The Board Of Trustees Of The Leland Stanford Junior University Fusion protein constructs
JP5492563B2 (ja) 2006-12-12 2014-05-14 バイオレクシス ファーマシューティカル コーポレーション トランスフェリン融合タンパク質ライブラリー
US7816324B2 (en) 2007-03-13 2010-10-19 Board Of Regents, The University Of Texas System Composition and method for the treatment of diseases affected by a peptide receptor
WO2008133928A2 (en) * 2007-04-27 2008-11-06 The Gi Company, Inc. Mucin glycoproteins and their use for treatment of epithelial lesions and mucin dependent disorders
EP2185701A4 (en) * 2007-08-15 2011-03-02 Amunix Operating Inc COMPOSITIONS AND METHODS FOR ENHANCING THE PRODUCTION OF RECOMBINANT POLYPEPTIDES
DE102007049830A1 (de) 2007-10-16 2009-04-23 Henkel Ag & Co. Kgaa Neue Proteinvarianten durch zirkulare Permutation
EP2050759A1 (en) 2007-10-19 2009-04-22 CONARIS research institute AG Soluble gp 130 muteins with improved binding activity
US9687559B2 (en) 2008-03-19 2017-06-27 The Board Of Regents Of The University Of Oklahoma Heparosan polymers and methods of making and using same for the enhancement of therapeutics
WO2009148946A2 (en) * 2008-05-29 2009-12-10 The Board Of Trustees Of The Leland Stanford Junior University Cell line, system and method for optical control of secondary messengers
WO2009153960A1 (ja) * 2008-06-17 2009-12-23 大塚化学株式会社 糖鎖付加ｇｌｐ－１ペプチド
GB0815216D0 (en) * 2008-08-21 2008-09-24 Asterion Ltd Interleukin
SI2393828T1 (sl) * 2009-02-03 2017-01-31 Amunix Operating Inc. Podaljšani rekombinantni polipetidi in sestavki, ki jih obsegajo
EP2432476A4 (en) * 2009-05-01 2013-03-20 Ophthotech Corp METHOD FOR THE TREATMENT OR PREVENTION OF EYE DISEASES
WO2011103049A2 (en) * 2010-02-16 2011-08-25 Immune Disease Institute, Inc. Method for screening receptors/ligands interactions
EP2553101A4 (en) 2010-04-02 2013-09-04 Univ Rochester PROTEASE-ACTIVATED CYTOKINES
US9119869B2 (en) 2010-04-29 2015-09-01 Ronald J. Shebuski Mucin derived polypeptides
BR112013003646B1 (pt) * 2010-07-29 2021-09-08 Eleven Biotherapeutics, Inc. Proteína isolada que compreende um domínio de citocina da família de interleucina-1 (il-1) quimérica, seu método de preparação, composição farmacêutica e usos, bem como, ácido nucleico, vetor, e célula hospedeira
US9511151B2 (en) * 2010-11-12 2016-12-06 Uti Limited Partnership Compositions and methods for the prevention and treatment of cancer
US9745359B2 (en) * 2012-05-18 2017-08-29 Adda Biotech Inc. Protein and protein conjugate for diabetes treatment, and applications thereof
NZ630848A (en) * 2012-06-08 2016-07-29 Alkermes Inc Fusion polypeptides comprising an active protein linked to a mucin-domain polypeptide

Also Published As

Publication number Publication date
AU2013271542A1 (en) 2014-10-16
PL2859015T3 (pl) 2018-08-31
HK1210055A1 (en) 2016-04-15
HRP20201973T1 (hr) 2021-02-05
AU2013271545C1 (en) 2017-09-28
WO2013184938A2 (en) 2013-12-12
EP3401402B1 (en) 2020-10-14
US9156897B2 (en) 2015-10-13
EP2874639A4 (en) 2016-05-11
WO2013184938A3 (en) 2014-01-30
JP2018038389A (ja) 2018-03-15
AU2013271542B2 (en) 2016-07-14
JP6234446B2 (ja) 2017-11-22
EP2859015A4 (en) 2015-11-18
JP6388408B2 (ja) 2018-09-12
RS61391B1 (sr) 2021-02-26
CA2869787C (en) 2021-11-23
NZ715099A (en) 2018-12-21
LT3401402T (lt) 2020-12-28
WO2013184939A2 (en) 2013-12-12
JP2015525217A (ja) 2015-09-03
NZ630851A (en) 2016-07-29
US20130336924A1 (en) 2013-12-19
AU2013271541B2 (en) 2016-03-17
WO2013184942A1 (en) 2013-12-12
AU2013271545A1 (en) 2014-10-16
EP2859015A1 (en) 2015-04-15
CA2869786A1 (en) 2013-12-12
JP7048543B2 (ja) 2022-04-05
SMT202100007T1 (it) 2021-03-15
TR201809046T4 (tr) 2018-07-23
AU2013271545B2 (en) 2016-03-03
CY1124525T1 (el) 2022-07-22
US20130338067A1 (en) 2013-12-19
EP2874639A2 (en) 2015-05-27
DK3401402T3 (da) 2021-01-11
AU2013271541A1 (en) 2014-10-23
US20200040053A1 (en) 2020-02-06
US9296801B2 (en) 2016-03-29
US10023623B2 (en) 2018-07-17
US9428563B2 (en) 2016-08-30
ES2675568T3 (es) 2018-07-11
HUE052908T2 (hu) 2021-05-28
EP2858672A4 (en) 2016-02-10
SI2859015T1 (sl) 2018-12-31
JP6545759B2 (ja) 2019-07-17
ES2675784T3 (es) 2018-07-12
DK2859015T3 (en) 2018-06-18
NZ630848A (en) 2016-07-29
CY1120522T1 (el) 2019-07-10
NZ630849A (en) 2016-04-29
EP2858672A2 (en) 2015-04-15
PT3401402T (pt) 2020-11-11
ES2667558T3 (es) 2018-05-11
JP2023109948A (ja) 2023-08-08
US20160237132A1 (en) 2016-08-18
SI3401402T1 (sl) 2021-03-31
US20160052983A1 (en) 2016-02-25
EP2859015B1 (en) 2018-03-21
JP2019195332A (ja) 2019-11-14
JP2015525216A (ja) 2015-09-03
HRP20180914T1 (hr) 2018-07-27
JP2022050391A (ja) 2022-03-30
EP3401402A1 (en) 2018-11-14
CA2869787A1 (en) 2013-12-12
ES2842677T3 (es) 2021-07-14
JP6322626B2 (ja) 2018-05-09
HUE037849T2 (hu) 2018-09-28
EP2858672B1 (en) 2018-04-04
US9359415B2 (en) 2016-06-07
JP7350041B2 (ja) 2023-09-25
TR201808753T4 (tr) 2018-07-23
US20140234962A1 (en) 2014-08-21
EP2874639B1 (en) 2018-03-28
US20170044228A1 (en) 2017-02-16
US10407481B2 (en) 2019-09-10
RS57369B1 (sr) 2018-08-31
JP2015520193A (ja) 2015-07-16
CA2869674A1 (en) 2013-12-12
US10183979B2 (en) 2019-01-22
PT2859015T (pt) 2018-06-26
WO2013184939A3 (en) 2014-01-30
US20130336925A1 (en) 2013-12-19
HK1203969A1 (en) 2015-11-06
EP3825405A1 (en) 2021-05-26
LT2859015T (lt) 2018-07-10
AU2013271541C1 (en) 2018-01-18
HK1203820A1 (en) 2015-11-06
PL3401402T3 (pl) 2021-05-31
SMT201800363T1 (it) 2018-09-13

Similar Documents

Publication Publication Date Title
HRP20180914T1 (hr) Ligandi modificirani cirkularnom permutacijom kao agonisti i antagonisti
EP2940901A4 (en) Display method
DK3293183T3 (da) Hæmmerforbindelser
CO6990736A2 (es) Pirrolidina-2-carboxamidas sustituídas
JP2012236821A5 (ja) 有機金属錯体
BR112014032798A2 (pt) composição
EP2925745A4 (en) Cxcr7 antagonists
EP2803885A4 (en) MIXER
DE112013004614T8 (de) Gestentastatur mit Gestenannullierung
SMT201600441B (it) Nuovi agenti antimalarici
DK2836494T3 (da) Nye alkyleringsmidler
FI20126335A (fi) Ovenlukko
BR112014032712A2 (pt) composição
DK2914574T3 (da) Ny fremgangsmåde
RS55034B1 (sr) Transdermalno sredstvo koje uključuje porozne mikročestice
EP2837670A4 (en) Fluorobiphenyl-containing composition
FR2985656B1 (fr) Oxymetre
BR302013001095S1 (pt) Configuração aplicada em mixer
DK2849764T3 (da) Sporstofopløsning
DE102012001057A8 (de) Bauteil
BR302013001096S1 (pt) Configuração aplicada em mixer
DK2719849T3 (da) Lås
DE112013001653A5 (de) Carben-Übertragungsreagenz
DK2800573T3 (da) Oftalmologisk sammensætning
DE112013005702A5 (de) Pfosten